COVID-19 PANDEMIC - UPDATE
Since the late 2019 onset of Coronavirus in Asia, NUVISAN’s management has been following the development of the disease, assessing its potential impact and anticipated precautionary measures to make sure employees are safe and to secure business continuity.
INNOVATION CAMPUS BERLIN, a NUVISAN company, is part of the EU supported progamme CARE (Corona Accelerated R&D in Europe)
INNOVATION CAMPUS BERLIN is a proud Partner of Europe’s Largest Initiative to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats which is launched today in cooperation with the European Union, the European Federation of Pharmaceutical Industries, Associations (EFPIA) companies and IMI-Associated Partners.
NUVISAN starts the „INNOVATION CAMPUS BERLIN“ (ICB) with over 400 workplaces
On the 1st of July, the "INNOVATION CAMPUS BERLIN" (ICB), a subsidiary of NUVISAN GmbH/ Neu-Ulm officially opened. NUVISAN has taken over a large part of the Berlin-based pharmaceutical research unit, focused on the field of small molecule active ingredients, from Bayer AG and agreed on a strategic partnership.
DRUG SUBSTANCE MANUFACTURING
>> Now with GMP Grade
With our GMP Certification we are today supporting you all the way to the first stages of Clinical Development. By doing so, we strengthen further the Extension of our Service Range, up to delivery of Tumkey Solutions for Phase I & II Batch Production.
FORMULATION SCIENCE AND TECHNOLOGY GROUP
Our Formulation Science and Technology group provides a technology platform founded on 30 years of experience creating industry leading topical products. Located on the French Rivera at the former Galderma worldwide R&D center staffed with experts responsible for innovating and developing iconic topical products.
NUVISAN AT THE FOREFRONT TO FIGHT THE CORONAVIRUS
The world is currently facing a challenge unforeseen in decades.
To combat this threat, NUVISAN GmbH is fully focused on its mission: to contribute to the general health of all, not only as a service provider but also as a socially responsible business entity.
There are many ways in which we feel we can help our community fight the virus and decrease the impact it has on our society. As a key player in the drug development arena we understand how we can influence the way things evolve for the good of all; by supporting the pharmaceutical community as we have over the last 40 years.
COVID-19 OUTBREAK - UPDATE V2
Since the late 2019 onset of COVID-19 (Coronavirus) in Asia, NUVISAN´s management has been closely following the spread of the virus and the development of the disease as well as the measures adopted by local governments aimed to contain the further spread of the virus, assessing their potential impact and anticipated precautionary measures.
With Covid-2019 now at the stage of pandemic, NUVISAN has taken strict measures as per its social and business responsibilities. As of today the peak of the outbreak seems not to have been reached and we shall take all precautions to contain and protect, in all aspects. First and foremost, the general public health, the ones of our employees, partners and visitors is our major focus and as an active player in the health industry NUVISAN has taken strong measures for containment and safety of all:
NUVISAN and Bayer create new research unit in Berlin
Neu-Ulm/ Berlin, February 10, 2020 – NUVISAN has agreed with Bayer to integrate large parts of Bayer’s Berlin-based small molecule research unit and complements hereby its services in the field of preclinical research. NUVISAN is an international service provider for clinical studies, laboratory services and contract manufacturing (CRO / CDMO) with several sites and clinics in Germany and France. The strategic partnership will lay the foundation for a new research entity to be established by NUVISAN in Berlin and confirms the longstanding cooperation between the two companies.
NUVISAN continues steady growth by acquiring Inamed GmbH
On November 1st, the NUVISAN group announced the acquisition of Inamed GmbH. Inamed is an international CRO, specialized in clinical trials with patients that suffer respiratory and rare diseases.
This includes access to patient populations that are very difficult to recruit, such as patients with Cystic Fibrosis. Furthermore Inamed is one of very few CROs offering orally inhaled products flow profile studies with a combination of all associated skills (technical preparation of devices, flow-profile measurements, in house clinical performance, and management of some external pediatric sites) at the same CRO. Over the last several years NUVISAN and Inamed built up a close partnership through collaboration on a number of services. The current merger is the logical consequence of their long lasting successful cooperation.
The NUVISAN group continues steady growth by acquiring STRATEC Molecular GmbH
On April 1, the majority shareholder of the NUVISAN Group announced the acquisition of INVITEK Molecular GmbH (formerly STRATEC Molecular GmbH).
The newly founded company will be part of the NUVISAN group from 01.04.2019. To underline its commitment to developing and commercializing innovative and high-quality nucleic acid purification solutions, the company has been renamed INVITEK Molecular GmbH
At the Berlin location, the company will focus on the areas of oncology, infectious disease and microbiome research, and operate as system and OEM partner for leading in-vitro diagnostics companies. In the future, the Berlin-based company plans to concentrate on emerging molecular diagnostics applications such as liquid biopsy.
THE NUVISAN GROUP continues its growth by adding parts of the GALDERMA R&D capabilities from NESTLÉ SKIN HEALTH
On August 31st the NUVISAN GROUP, one of Europe´s leading CRO´s focused on early stage drug development for the life science industry, signed an agreement with NESTLÉ SKIN HEALTH/ GALDERMA to take over parts of the R&D capacities in Sophia-Antipolis, France.
The GALDERMA R&D site in Sophia-Antipolis which opened in 2006 is the world’s largest research and development center focused on medical and cosmetic solutions for the skin. The new capabilities will strengthen NUVISAN’S core service lines in Bioanalysis, Clinical Trial Supplies and Pharmaceutical Analytics as well as enhancing the portfolio by adding GMP-API synthesis and formulation capability for prescription drugs and cosmetics. NUVISAN intends to start its operations in Sophia Antipolis in October 2018.